Matrix platemate

Manufactured by Thermo Fisher Scientific

Sourced in United States

The Matrix Platemate is a liquid handling instrument designed for precise and accurate dispensing of small volumes of liquids. It is capable of handling a wide range of sample types and volumes, making it suitable for various laboratory applications.

Automatically generated - may contain errors

Lab products found in correlation

Transfection reagent, by Promega (1 mentions) Matrix wellmate, by Thermo Fisher Scientific (1 mentions) Britelite plus, by PerkinElmer (1 mentions) Prism 6, by GraphPad (1 mentions) Celltiter glo assay, by Promega (1 mentions) Envision multilabel plate reader, by PerkinElmer (1 mentions)

2 protocols using matrix platemate

NOTCH1 Gain-of-Function Screen with Luciferase Reporter

Check if the same lab product or an alternative is used in the 5 most similar protocols

The cDNA screening strategy involved the use of three key components: 1)
a pcDNA3 plasmid encoding a modestly strong NOTCH1gain-of-function mutant, L1601PΔP, driven from a CMV promoter (40 ng of
cDNA/well), 2) a Notch firefly luciferase reporter (TP1) containing 12 CSL
binding sites (50 ng of cDNA/well), and 3) a pre-plated cDNA library cloned into
the Sport6 plasmid (40 ng of cDNA/well). A MAML1 cDNA was the
positive control for each screen plate, while empty vector and a
DTX1 cDNA were background and negative controls (40 ng of
cDNA/well) respectively. DNA spotting was performed using a Matrix Platemate
(Thermo, Waltham, MA, USA) for the control wells. The Matrix Wellmate (Thermo)
was used to dispense the transfection mix containing the reporter and Notch1
mutant plasmids in combination with transfection reagent (Fugene6 Promega),
which were added to the wells (4000 U20S cells/well) after a 30 min incubation.
Luminescence was measured 48 hours after plating using BriteLite-Plus
(PerkinElmer, Waltham, MA, USA) luciferase reagent with LJL Biosystems Analyst
HT96:384. Methods for screen validation are provided in the supplementary materials.

Pajcini K.V., Xu L., Shao L., Petrovic J., Palasiewicz K., Ohtani Y., Bailis W., Lee C., Wertheim G.B., Mani R., Muthusamy N., Li Y., Meijerink J.P., Blacklow S.C., Faryabi R.B., Cherry S, & Pear W.S. (2017). MafB is a novel enhancer of oncogenic Notch signaling in T-cell acute lymphoblastic leukemia. Science signaling, 10(505), eaam6846.

+ Open protocol

+ Expand

Cell Viability Assay for Drug Potency

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells
were harvested, resuspended,
and plated with a Wellmate liquid handler (Thermo Scientific) into
384-well plates and cultured for 24 h before dosing. Master compound
plates were made with a Janus (PerkinElmer), then further diluted
to achieve uniform final concentrations of DMSO of 0.1% in media for
all treatment conditions. Compound treatments in media were added
to the cell plates with a Matrix Platemate (Thermo Scientific). Cell
viabilities were determined 72 h after treatment by Cell-Titer Glo
assay (Promega) on the Envision multilabel plate reader (PerkinElmer).
Relative luminescent units (RLU) were plotted against corresponding
drug concentrations and fitted with a standard four-parameter sigmoidal
curve with GraphPad Prism 6. Data were further fit for EC₅₀ shift parameters in GraphPad Prism 6 to determine EC₅₀ ratios for 1/2. Data are reported as the
EC₅₀ ratio, and error bars represent SEM (n = 3). Data for cell lines in which EC₅₀ ratio fits were
ambiguous, R² values were less than 0.9,
or response to the free drug was less than 40% were not reported.

Spangler B., Fontaine S.D., Shi Y., Sambucetti L., Mattis A.N., Hann B., Wells J.A, & Renslo A.R. (2016). A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. Journal of Medicinal Chemistry, 59(24), 11161-11170.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!